Accredited Podcast Episodes

Oncology Data Advisor™ · Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States (ACS, 2022). The mortality rate has increased approximately 1% each year from 2015 to 2019, an increase which may be related to a higher rate of advanced-stage ca...
Oncology Data Advisor™ · New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia Chemotherapy-induced neutropenia (CIN) is a potentially life-threatening toxicity of chemotherapy that has been recognized as a major risk factor for the development of infections in patients with cancer (NCCN, 2021). The severity and duration of neutropenia place patients at higher risk of developing febrile neutropenia (FN) and experiencing dose reductions or delays that may comprom...
Oncology Data Advisor™ · Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 84% of cases are classified as non–small cell lung cancer (NSCLC) (ACS, 2022). Though new screening procedures have identified more lung cancers at an earlier stage, most patients are still diagnosed at a locally advanced or metast...
Oncology Data Advisor™ · Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul Banerjee In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma. Rahul Banerj...
Oncology Data Advisor™ · Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer Squamous cell lung carcinoma is a distinct histologic subtype of non–small cell lung cancer (NSCLC) that accounts for approximately 25% to 30% of all NSCLC cases and is associated with approximately 30% shorter survival compared with other subtypes of the disease. Because alterations and mutations for which targeted therapies are approved are uncommon in squamous cell NSCLC, treatment re...

Copyright © 2022 Oncology Data Advisor. All rights reserved.